Novo Nordisk A/S ADR (NVO)

$133.18 1.64 (1.25%)

19:00 EDT NVO Stock Quote Delayed 30 Minutes

70 Trades To Make Now That Rates May Rise

By Louis Navellier, Editor, Growth Investor Mar 25, 2014

It's a bit of a strange market, with investors reacting to 'news' like Yellen's comments and Crimea. Make some sense of it with these trading ideas

52 Trades to Beat the Mutual Fund Slump

3 Huge Healthcare Trends Can Fatten Your Portfolio

3 Ways to Trade Diabetes Treatment

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 3.72M

Day's Range $131.85 - $133.26

52-Week Range $77.96 - $148.15

Dividend & Yield $1.77 (1.33%)

NVO Stock Predictions, Articles, and Novo Nordisk A/S ADR News

Winners After Novo Nordisk’s Insulin Rejection

By James Brumley, InvestorPlace Feature Writer Feb 14, 2013

Eli Lilly and Sanofi look like the biggest players that are best suited to benefit from Novo Nordisk's diabetes-drug setback, but a smaller player could emerge, too.

Little News, Little Wiggle — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor Feb 11, 2013

A slow Monday featured a lack of economic or earnings news and led investors to mostly sit on the sidelines for the day.

3 Healthcare Stocks Ready for a Breather

By Will Ashworth, InvestorPlace Contributor Feb 6, 2013

It's the hottest sector in the S&P 500 so far this year, and that means some big-name pullbacks are likely. Here are three likely candidates.

Laying Out Our Strategy for the Second Half of 2012

By Hilary Kramer, Editor, GameChangers Jul 5, 2012

The rest of the year will be driven in large part by four factors. See what they are -- and which five stocks are in a strong position to do well.

Earnings Season Brings Joy or Sorrow

By Louis Navellier, Editor, Growth Investor Apr 18, 2012

Earnings season is difficult for everyone, as winners tend to get big stock bumps, while losers tend to go the other way: down. Hang on!

Here Comes a Bidding War for Amylin

By Gene Marcial, InvestorPlace Contributor Apr 2, 2012

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.